iShares Core High Dividend ETF(HDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HDV iShares Core High Dividend ETF

Post-Mkt 04-25 18:43:28 EDT

113.84

-0.06

-0.05%

盘后115.99

+2.15+1.89%

17:12 EDT

High114.00	Low112.71	Vol237.50K
Open113.82	D1 Closing113.90	Amplitude1.13%
Mkt Cap10.89B	Tradable Cap10.89B	Total Shares95.65M
T/O26.98M	T/O Rate0.25%	Tradable Shares95.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"HDV","market":"US","secType":"STK","nameCN":"iShares Core High Dividend ETF","latestPrice":113.84,"timestamp":1745611200000,"preClose":113.9,"halted":0,"volume":237503,"hourTrading":{"tag":"盘后","latestPrice":115.99,"preClose":113.84,"latestTime":"17:12 EDT","volume":7,"amount":798.18998,"timestamp":1745615561965},"delay":0,"floatShares":95650000,"shares":95650000,"eps":0,"marketStatus":"Post-Mkt","change":-0.06,"latestTime":"04-25 18:43:28 EDT","open":113.82,"high":114,"low":112.71,"amount":26981601.94093,"amplitude":0.011326,"askPrice":126.01,"askSize":100,"bidPrice":109.84,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745625600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":113.9,"sharesOutstanding":95650000,"nav":113.589524,"aum":10864837970.6,"dividendRate":0.035796,"bidAskSpread":0.000449,"preHourTrading":{"tag":"盘前","latestPrice":114,"preClose":113.9,"latestTime":"09:21 EDT","volume":36,"amount":4100.50008,"timestamp":1745587286506},"postHourTrading":{"tag":"盘后","latestPrice":115.99,"preClose":113.84,"latestTime":"17:12 EDT","volume":7,"amount":798.18998,"timestamp":1745615561965},"volumeRatio":0.37062,"impliedVol":0.1799,"impliedVolPercentile":0.932},"requestUrl":"/m/hq/s/HDV/tweets","defaultTab":"tweets","newsList":[{"id":"2526385370","title":"Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2526385370","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526385370?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 14:00","pubTimestamp":1744178400,"startTime":"0","endTime":"0","summary":"– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations – – Additional p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/09/3058117/16259/en/Assembly-Biosciences-Presents-New-Data-Highlighting-Long-Acting-Herpes-Simplex-Virus-Candidate-ABI-5366-and-Genital-Herpes-Prevalence-and-Treatment-Patterns-at-the-2025-ESCMID-Cong.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASMB","HDV","PK","BK4181","BK4218","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2521496941","title":"Press Release: Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2521496941","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521496941?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 04:05","pubTimestamp":1742501100,"startTime":"0","endTime":"0","summary":"-- Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline --. -- Interim Phase 1b proof-of-concept data, including initial efficacy measures, anticipated in fall 2025 for ABI-5366 and ABI-1179, long-acting helicase-primase inhibitor candidates for recurrent genital herpes --. SOUTH SAN FRANCISCO, Calif., March 20, 2025  -- Assembly Biosciences, Inc. , a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the year ended December 31, 2024, and recent highlights.\"We are well-positioned to deliver important clinical data on four of our novel antiviral candidates in 2025, including proof-of-concept efficacy data expected this fall from the Phase 1b studies of ABI-5366 and ABI-1179 for recurrent genital herpes,\" said Jason Okazaki, chief executive officer and president of Assembly Bio. \"We anticipate that the rapid progress across our clinical ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4218","BK4588","BK4181","HDV","BK4139","PK","ASMB"],"gpt_icon":0},{"id":"2519836627","title":"Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta","url":"https://stock-news.laohu8.com/highlight/detail?id=2519836627","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519836627?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:05","pubTimestamp":1741867500,"startTime":"0","endTime":"0","summary":"First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment. Rapid study start indicative of significant unmet need for chronic hepatitis delta treatment. SAN FRANCISCO, March 13, 2025----Vir Biotechnology, Inc.  today announced the enrollment of the first patient in its Phase 3 ECLIPSE registrational program. The ECLIPSE registrational program is designed to evaluate the efficacy and safety of tobevibart in combination with elebsiran in people living with chronic hepatitis delta . ECLIPSE 1, the first trial of the program to be initiated, and ECLIPSE 2 are Phase 3 trials designed to provide the registrational data needed for submission to multiple regulatory agencies. ECLIPSE 3, a Phase 2b trial, is designed to provide important supportive data to help enable access and reimbursement strategies in key European markets.The significant unmet need in CHD and the potential for tobevibart and elebsir","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-enrolls-first-patient-120500531.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","VIR","BK4568","CHD","BK4139","LU1585245621.USD","HDV","BK4018","BK4535","LU1430594728.SGD","BK4588","BK4504"],"gpt_icon":0},{"id":"2514837055","title":"Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus","url":"https://stock-news.laohu8.com/highlight/detail?id=2514837055","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514837055?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:00","pubTimestamp":1740574800,"startTime":"0","endTime":"0","summary":"– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/26/3032858/16259/en/Assembly-Biosciences-Doses-First-Participant-in-Phase-1a-Clinical-Study-of-Oral-Entry-Inhibitor-Candidate-ABI-6250-for-Hepatitis-Delta-Virus.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4181","BK4218","BK4585","HDV","BK4139","PK","ASMB"],"gpt_icon":0},{"id":"2507655189","title":"HEXAOM Strengthens Market Position with HDV Group Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2507655189","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507655189?lang=en_us&edition=full_marsco","pubTime":"2025-01-30 01:06","pubTimestamp":1738170360,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Hexaom SA ( ($FR:ALHEX) ). HEXAOM has acquired 75.5% of the HDV Group, a company with extensive experience in h...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hexaom-strengthens-market-position-with-hdv-group-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hexaom-strengthens-market-position-with-hdv-group-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","HDV","BK4585"],"gpt_icon":0},{"id":"2494585774","title":"Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B","url":"https://stock-news.laohu8.com/highlight/detail?id=2494585774","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494585774?lang=en_us&edition=full_marsco","pubTime":"2024-12-26 21:00","pubTimestamp":1735218000,"startTime":"0","endTime":"0","summary":"– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed –  – In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/26/3001938/16259/en/Assembly-Biosciences-Reports-Interim-Phase-1b-Results-from-Clinical-Trial-Evaluating-Next-Generation-Capsid-Assembly-Modulator-Candidate-ABI-4334-in-Chronic-Hepatitis-B.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HDV","BK4599","BK4139","BK4181","ASMB","ALT","BK4218","BK4585","BK4588","LU1878469433.USD","PK"],"gpt_icon":0},{"id":"2493743774","title":"Hexaom SA Expands with HDV Group Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2493743774","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493743774?lang=en_us&edition=full_marsco","pubTime":"2024-12-24 16:02","pubTimestamp":1735027339,"startTime":"0","endTime":"0","summary":"Hexaom SA (FR:ALHEX) has released an update. Hexaom SA has signed an agreement to acquire a 75.5% stake in the HDV Group, a house builder based in ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hexaom-sa-expands-with-hdv-group-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hexaom-sa-expands-with-hdv-group-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","HDV","BK4585"],"gpt_icon":0},{"id":"2492127968","title":"Press Release: Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2492127968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492127968?lang=en_us&edition=full_marsco","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":"Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs. --Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending cash runway to mid-2026--. Funding received from Gilead will support the advancement of Assembly Bio's clinical pipeline of antiviral therapeutic candidates for herpesviruses, hepatitis D virus  and hepatitis B virus . Assembly Bio expects to release data from multiple ongoing clinical studies in the coming year, including the interim Phase 1b proof-of-concept data readout for ABI-5366 projected for the first half of 2025.Since the collaboration with Gilead was announced in October 2023, Assembly Bio has initiated clinical studies for four small molecule antiviral candidates. In mid-2024, a Phase 1a/b study for ABI-5366, a long-acting helicase-primase inhibitor for treatment of recurrent genital herpes a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","EQR","ASMB","BK4585","BK4215","HDV"],"gpt_icon":0},{"id":"2491354421","title":"Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta","url":"https://stock-news.laohu8.com/highlight/detail?id=2491354421","media":"Business Wire","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491354421?lang=en_us&edition=full_marsco","pubTime":"2024-12-13 05:05","pubTimestamp":1734037500,"startTime":"0","endTime":"0","summary":"– Designations aim to expedite the development and review of promising therapies for serious conditions with unmet medical needs –。SAN FRANCISCO, December 12, 2024----Vir Biotechnology, Inc.  today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration  Breakthrough Therapy designation and European Medicines Agency  Priority Medicines  designation for the treatment of chronic hepatitis delta . The designations are supported by compelling positive safety and efficacy data from the Phase 2 SOLSTICE trial, from which the Company recently presented new data at AASLD The Liver Meeting in San Diego, U.S. Vir Biotechnology’s Phase 3 ECLIPSE registrational program evaluating tobevibart and elebsiran in CHD will commence in the first half of 2025.SOLSTICE is a Phase 2 study to evaluate the safety, tolerability, and efficacy of tobevibart,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wXNPCu3vSLcC52uz19vPqw--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bb9e8dae459d7a75ec75adc12df64de0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wXNPCu3vSLcC52uz19vPqw--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bb9e8dae459d7a75ec75adc12df64de0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-receives-fda-breakthrough-210500608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4018","BK4599","BK4568","CHD","BK4588","VIR","HDV","BK4504","LU1878469433.USD","BK4079","BK4585","COMP","BK4539","BK4535","ALT","BK4139"],"gpt_icon":0},{"id":"2484956973","title":"Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2484956973","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484956973?lang=en_us&edition=full_marsco","pubTime":"2024-11-19 10:15","pubTimestamp":1731982500,"startTime":"0","endTime":"0","summary":"– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 –。– Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts –。– Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares –。– Following a recent FDA meeting, Phase 3 ECLIPSE registrational program to begin in the first half of 2025 –。These data were presented in an oral session at the American Association for the Study of Liver Diseases  The Liver Meeting, in San Diego, CA. Based on these results, and following a recent meeting with the FDA, Vir Biotechnology plans to initiate the Phase 3 registrational ECLIPSE program in the first half of 2025 to further evaluate the combination of tobevibart and elebsiran for the treatment of CHD.Primary Endpoint Analysis from the Phase 2 SOLSTICE Tria","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/l5oi2o6BXS3LWePoIaxyng--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4cd04e41299f5f946a2db3e8d5341040","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/l5oi2o6BXS3LWePoIaxyng--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4cd04e41299f5f946a2db3e8d5341040"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-presents-positive-chronic-021500234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALT","HDV","COMP","BK4504","BK4139","BK4588","BK4539","BK4535","LU1878469433.USD","BK4585","RNA","CHD","VIR","BK4018","BK4568","BK4079","BK4505"],"gpt_icon":0},{"id":"2484987837","title":"Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2484987837","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484987837?lang=en_us&edition=full_marsco","pubTime":"2024-11-19 05:05","pubTimestamp":1731963900,"startTime":"0","endTime":"0","summary":"– Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need –。– Phase 2 SOLSTICE 24-week primary endpoint data for tobevibart and elebsiran in chronic hepatitis delta to be presented today at AASLD The Liver Meeting –。SAN FRANCISCO, November 18, 2024----Vir Biotechnology, Inc.  today announced that the European Medicines Agency  Committee for Orphan Medicinal Products , has issued a positive opinion on the application for orphan drug designation of tobevibart and elebsiran for the treatment of chronic hepatitis delta . This opinion is based on encouraging preliminary data from the Phase 2 SOLSTICE trial. Vir Biotechnology will present 24-week data from the Phase 2 SOLSTICE trial at AASLD The Liver Meeting in San Diego, CA, on November 18 at 6.15 p.m. PT. An investor conference call is scheduled for November 19, 2024, at 5.15 a.m. PT / 8.15 a.m. ET.In June 2024, the U.S. Food and Drug Adm","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7t3Zh_oOq.Ev7QwyfJfJ7A--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c6e8102cbc679b8da4fd51cdf0d22878","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7t3Zh_oOq.Ev7QwyfJfJ7A--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c6e8102cbc679b8da4fd51cdf0d22878"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-receives-positive-opinion-210500380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALT","BK4018","BK4585","COMP","LU1878469433.USD","HDV","BK4139","BK4568","BK4539","CHD","MDCO","VIR","BK4504","BK4535","BK4588","BK4079"],"gpt_icon":0},{"id":"2481316725","title":"Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481316725","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481316725?lang=en_us&edition=full_marsco","pubTime":"2024-11-08 05:05","pubTimestamp":1731013500,"startTime":"0","endTime":"0","summary":"Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral dosing. First participants dosed in Phase 1b trial evaluating ABI-5366 in individuals with recurrent genital herpes with interim data expected in first half of 2025. Phase 1b trial for ABI-4334, a next-generation highly potent capsid assembly modulator candidate, ongoing in participants with chronic HBV with interim data expected by end of year. ABI-1179 and ABI-6250 candidates on track to enter clinic by end of year. “I’m thrilled with the continued execution against our ambitious goal of advancing four candidates targeting serious viral diseases in the clinic and releasing two interim data sets by year end,” said Jason Okazaki, chief executive officer and president of Assembly Bio. “We recently reported positive interim Phase 1a data for ABI-5366 that exceeded our expectations and supporte","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/by7HdGeYi.U8vLYly8kKRw--~B/aD00NjE7dz0yMjI3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/460d964ae4991b15a5864572dea0f515","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/by7HdGeYi.U8vLYly8kKRw--~B/aD00NjE7dz0yMjI3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/460d964ae4991b15a5864572dea0f515"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/assembly-biosciences-reports-third-quarter-210500996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ASMB","BK4139","BK4585","BK4588","HDV"],"gpt_icon":0},{"id":"2475872634","title":"HDV: An Inferior Alternative To SCHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2475872634","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475872634?lang=en_us&edition=full_marsco","pubTime":"2024-10-15 23:26","pubTimestamp":1729005997,"startTime":"0","endTime":"0","summary":"Funtap The iShares Core High Dividend ETF (NYSEARCA:HDV) is a decent, but not great ETF option for investors that want to create a steady stream of dividend income. While the iShares Core High Dividend ETF has some strengths, I believe that the","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1544761799/image_1544761799.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1544761799/image_1544761799.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4726881-hdv-an-inferior-alternative-to-schd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_fund","symbols":["BK4588","BK4550","FDN","BK4585","HDV","SCHD"],"gpt_icon":0},{"id":"2475064525","title":"Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2475064525","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475064525?lang=en_us&edition=full_marsco","pubTime":"2024-10-15 20:16","pubTimestamp":1728994560,"startTime":"0","endTime":"0","summary":"– Phase 2 SOLSTICE Safety and Efficacy Data in Hepatitis Delta Trial at Week 24 to Be Presented –。– Oral and Five Poster Presentations Highlight Important Progress in Hepatitis Delta and Hepatitis B Clinical Programs, and Deliver Key Insights on the Burden of Disease Among Patient Segments in Hepatitis Delta –。SAN FRANCISCO, October 15, 2024----Vir Biotechnology, Inc.  today announced it will present new data from the Phase 2 SOLSTICE clinical trial evaluating the efficacy and safety profile of tobevibart, an investigational monoclonal antibody , and elebsiran, an investigational small interfering ribonucleic acid  for the potential treatment of chronic hepatitis delta.Pharmacokinetics and safety of a single dose of elebsiran  subcutaneously administered in adult participants with moderate renal impairment Session: Hepatitis BDate: November 15Time: 1:00 – 2:00 p.m. PTPresenter: Li Wang, Associate Director, Clinical Pharmacology, Vir Biotechnology, Inc.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Xd2vNcbDIfrDguahEAVWDg--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b16fd901da08fe1eb8f77b7593062751","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Xd2vNcbDIfrDguahEAVWDg--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b16fd901da08fe1eb8f77b7593062751"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-announces-clinical-advances-121600546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4504","BK4568","BK4585","CHD","VIR","BK4018","CHB","HDV","BK4535","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://us.ishares.com/product_info/fund/overview/HDV.htm","stockEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":-0.0384},{"period":"3month","weight":-0.0047},{"period":"6month","weight":-0.0314},{"period":"1year","weight":0.0381},{"period":"ytd","weight":0.0146}],"compareEarnings":[{"period":"1week","weight":0.0385},{"period":"1month","weight":-0.05},{"period":"3month","weight":-0.1008},{"period":"6month","weight":-0.0559},{"period":"1year","weight":0.0817},{"period":"ytd","weight":-0.0672}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.004553},{"month":2,"riseRate":0.714286,"avgChangeRate":0.007137},{"month":3,"riseRate":0.714286,"avgChangeRate":0.005163},{"month":4,"riseRate":0.666667,"avgChangeRate":0.01641},{"month":5,"riseRate":0.642857,"avgChangeRate":0.001333},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.004124},{"month":7,"riseRate":0.785714,"avgChangeRate":0.018143},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.005655},{"month":9,"riseRate":0.357143,"avgChangeRate":-0.015804},{"month":10,"riseRate":0.571429,"avgChangeRate":0.018481},{"month":11,"riseRate":0.785714,"avgChangeRate":0.024376},{"month":12,"riseRate":0.5,"avgChangeRate":-0.004293}],"exchange":"ARCA","name":"iShares Core High Dividend ETF","nameEN":"iShares Core High Dividend ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"iShares Core High Dividend ETF(HDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest iShares Core High Dividend ETF(HDV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"iShares Core High Dividend ETF,HDV,iShares Core High Dividend ETF股票,iShares Core High Dividend ETF股票老虎,iShares Core High Dividend ETF股票老虎国际,iShares Core High Dividend ETF行情,iShares Core High Dividend ETF股票行情,iShares Core High Dividend ETF股价,iShares Core High Dividend ETF股市,iShares Core High Dividend ETF股票价格,iShares Core High Dividend ETF股票交易,iShares Core High Dividend ETF股票购买,iShares Core High Dividend ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"iShares Core High Dividend ETF(HDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest iShares Core High Dividend ETF(HDV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction